Telemedicine in Outpatient Covid-19 Patients (COVID-SMART)
Covid-19, Cardiovascular Risk Factor
About this trial
This is an interventional treatment trial for Covid-19 focused on measuring SARS-CoV2, Covid-19, cardiovascular disease, telemedicine, ECG, SpO2
Eligibility Criteria
Inclusion Criteria:
- Confirmed SARS-CoV2 infection and clinical Covid-19 disease
- age ≥18 years
Presence of ≥1 relevan cardiovascular condition, defined as (or):
- atrial fibrillation
- systolic or diastolic heart failure
- LV ejection fraction <50%
- coronary artery disease with past PCI or CABG
- Past myocardial infarction
- diabetes mellitus
- arterial hypertension (treated or untreated)
- active smoking
- chronic obstructive lung disease
- obesity (BMI ≥30kg/m2)
- availability of smartphone and sufficient internet connectivity at home
- ability to use smartwatch
- informed consent to study participation and data protection concept
Exclusion Criteria:
- Participation in concurrent clinical trial
- indication for hospitalization at study entry
Sites / Locations
- LMU Klinikum
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Telemedicine Care
Control
Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.
Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.